文献速递免疫规划传染病防控与疫情报告

二价mRNA疫苗预防COVID-19相关住院和重症的持久性估计——有与无免疫缺陷条件的成人,VISION网络,2022年9月至2023年4月

Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2023-05-26

VISION网络评估了2022年9月13日至2023年4月21日期间≥18岁成人接种二价mRNA疫苗后预防COVID-19相关住院的疫苗有效性(VE)。接种后7-59天,无免疫缺陷成人的VE为62%(95%CI=57%-67%),有免疫缺陷成人为28%(95%CI=10%-42%);无免疫缺陷成人接种后120-179天VE降至24%(95%CI=12%-33%)。二价加强针提供最高保护,对ICU入住或院内死亡等关键结局的保护至少持续179天。

要点

  • 接种二价疫苗后7-59天,无免疫缺陷成人VE为62%(95%CI=57%-67%),有免疫缺陷成人为28%(95%CI=10%-42%)。
  • 无免疫缺陷成人接种后120-179天VE降至24%(95%CI=12%-33%),有免疫缺陷成人VE总体更低。
  • 二价加强针对ICU入住或院内死亡等关键结局的保护至少持续179天。

核心结论

  • 二价加强针提供最高保护,对关键结局的保护至少持续179天。
  • 这些数据支持更新的建议,允许某些高危人群额外选择二价COVID-19疫苗剂量。
  • 所有符合条件者应随时按建议接种COVID-19疫苗。

研究设计与样本

  • VISION网络评估2022年9月13日至2023年4月21日期间≥18岁成人接种二价疫苗后预防COVID-19相关住院的VE。
  • 研究对象包括有与无免疫缺陷条件的成人。

主要发现

  • 接种后7-59天对比未接种,无免疫缺陷成人VE为62%(95%CI=57%-67%),有免疫缺陷成人为28%(95%CI=10%-42%)。
  • 无免疫缺陷成人接种后120-179天VE降至24%(95%CI=12%-33%)。
  • 有免疫缺陷成人的VE总体低于无免疫缺陷成人。
  • 二价加强针对ICU入住或院内死亡等关键结局的保护至少持续179天。

关键数值与推荐

  • 2022年9月1日,CDC免疫实践咨询委员会(ACIP)建议≥12岁已完成至少一剂单价基础系列者接种单剂二价mRNA COVID-19加强针。

临床怎么用

  • 这些数据支持更新的建议,允许某些高危人群额外选择二价COVID-19疫苗剂量。
  • 所有符合条件者应随时按建议接种COVID-19疫苗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

On September 1, 2022, CDC's Advisory Committee on Immunization Practices (ACIP) recommended a single bivalent mRNA COVID-19 booster dose for persons aged ≥12 years who had completed at least a monovalent primary series. Early vaccine effectiveness (VE) estimates among adults aged ≥18 years showed receipt of a bivalent booster dose provided additional protection against COVID-19-associated emergency department and urgent care visits and hospitalizations compared with that in persons who had received only monovalent vaccine doses (1); however, insufficient time had elapsed since bivalent vaccine authorization to assess the durability of this protection. The VISION Network* assessed VE against COVID-19-associated hospitalizations by time since bivalent vaccine receipt during September 13, 2022-April 21, 2023, among adults aged ≥18 years with and without immunocompromising conditions. During the first 7-59 days after vaccination, compared with no vaccination, VE for receipt of a bivalent vaccine dose among adults aged ≥18 years was 62% (95% CI = 57%-67%) among adults without immunocompromising conditions and 28% (95% CI = 10%-42%) among adults with immunocompromising conditions. Among adults without immunocompromising conditions, VE declined to 24% (95% CI = 12%-33%) among those aged ≥18 years by 120-179 days after vaccination. VE was generally lower for adults with immunocompromising conditions. A bivalent booster dose provided the highest protection, and protection was sustained through at least 179 days against critical outcomes, including intensive care unit (ICU) admission or in-hospital death. These data support updated recommendations allowing additional optional bivalent COVID-19 vaccine doses for certain high-risk populations. All eligible persons should stay up to date with recommended COVID-19 vaccines.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Link-Gelles R, Weber ZA, Reese SE, et al. Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023. MMWR Morb Mortal Wkly Rep. 2023. PMID: 37227984. doi:10.15585/mmwr.mm7221a3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。